financetom
Business
financetom
/
Business
/
Israel-Hamas conflict: No impact on shipments yet, says GE Shipping CFO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Israel-Hamas conflict: No impact on shipments yet, says GE Shipping CFO
Oct 12, 2023 2:30 AM

Concerns are growing across industries regarding the potential trade disruptions stemming from the Israel-Hamas conflict. However, the shipping industry remains largely insulated so far, according to G Shivakumar, Executive Director and CFO of Great Eastern Shipping Co.

Share Market Live

NSE

"There is no impact on shipping currently,....it's not on the main trade routes, there is no impact on cargos either," he said in a chat with CNBC-TV18.

He said a seasonal rise in demand for oil tankers is due now. Crude oil tankers earn approximately $25,000 per day, while dry bulk prices have surged from around $10,000 per day to an impressive $25,000 to $30,000 per day for larger tankers, he said.

GE Shipping recently sold its 2006-built Supramax Dry Bulk Carrier, Jag Rohan, to a third-party buyer, with delivery expected in Q3. The sale was profitable, as the ship had been purchased when market conditions were less favourable, Shivakumar said.

In an earlier interaction, the company had stated that the offshore fleet comprising 19 supply vessels would come up for re-pricing in the next two years. GE Shipping will probably get a $40,000 per day rate for each of the vessels in the next year, which is a significant increase from previous rates, he noted.

GE Shipping is one of India's largest private shipping companies. It mainly transports liquid, gas, and solid bulk products. It operates in two segments: Shipping and Offshore.

Shares of GE Shipping were up a little over 1% today at around Rs 866 on the NSE. The stock has gained more than 8% over the past month.

Read Here | Israel-Hamas war could lead to higher insurance premiums, shipping costs: GTRI

(Edited by : Shweta Mungre)

First Published:Oct 12, 2023 11:30 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
NaaS Technology Receives Nasdaq Noncompliance Notice
NaaS Technology Receives Nasdaq Noncompliance Notice
Jun 20, 2025
04:49 PM EDT, 06/20/2025 (MT Newswires) -- NaaS Technology ( NAAS ) said late Friday it received a notice from Nasdaq for noncompliance with the listing rule related to maintaining a minimum $35 million market value of its class A shares. NaaS Technology ( NAAS ) is also non-compliant with listing standards, like maintaining the minimum $2.5 million of stockholders'...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Ensign Group Insider Sold Shares Worth $731,445, According to a Recent SEC Filing
Ensign Group Insider Sold Shares Worth $731,445, According to a Recent SEC Filing
Jun 20, 2025
04:48 PM EDT, 06/20/2025 (MT Newswires) -- Beverly B. Wittekind, Vice President and Chief Legal Officer, on June 18, 2025, sold 4,719 shares in Ensign Group ( ENSG ) for $731,445. Following the Form 4 filing with the SEC, Wittekind has control over a total of 38,679 common shares of the company, with 38,679 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1125376/000112537625000117/xslF345X05/wk-form4_1750452238.xml...
Incyte Says FDA Extends Review Period for Ruxolitinib Cream
Incyte Says FDA Extends Review Period for Ruxolitinib Cream
Jun 20, 2025
04:49 PM EDT, 06/20/2025 (MT Newswires) -- Incyte ( INCY ) said Friday the US Food and Drug Administration has extended the review period for the supplemental new drug application for ruxolitinib cream to treat children with mild to moderate atopic dermatitis. The prescription drug user fee act action date has been extended to Sept. 19, Incyte ( INCY )...
Copyright 2023-2026 - www.financetom.com All Rights Reserved